Form 144 Filer Information UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

Form 144

FORM 144

NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933

144: Filer Information

Filer CIK0001885841Filer CCCXXXXXXXIs this a LIVE or TEST Filing?Is LIVE INFORMATIONSubmission Contact InformationImage: Contact Information

Name Phone E-Mail Address

144: Issuer Information

Name of Issuer SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

CFO

Roivant Sciences Ltd.

UNITED KINGDOM

001-40782 7th Floor 50 Broadway

London

SW1H 0DB

Pulik Richard

44 207 400 3347

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value		Approximate Date of Sale	Socuritios
Common shares, \$0.0000000341740141 par value per share (Common Shares)	E*TRADE FINANCIAL CORPORATION 3 EDISON DRIVE ALPHARETTA GA 30005	4583	39184.65	758427350	05/01/2023	Nasdaq Global Market

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Date you

Nature of

Is Date

Amount of

Date of

Nature of

Class	Acquired	Acquisition Transaction	Person from Whom Acquired	this a Gift?	Donor Acquired	Securities Acquired	Payment	Payment *
Common Shares	04/28/2023	Restricted Stock Units granted under the Roivant Sciences Ltd. Amended and Restated 2015 Equity Incentive Plan	Roivant Sciences Ltd.			4583	05/01/2023 N/	A

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Richard Pulik c/o Roivant Sciences Ltd. 7th Floor, 50 Broadway London X0 SW1H 0DB	Common Shares	03/29/2023	4584	33692.4
Richard Pulik c/o Roivant Sciences Ltd. 7th Floor, 50 Broadway London X0 SW1H 0DB	Common Shares	03/01/2023	4583	37076.47

144: Remarks and Signature

Remarks	The securities included in Table I represent a maximum number of shares that may be sold to cover the reporting person's tax obligations when restricted stock units belonging to the reporting person are settled. The securities reported in Table I do not represent discretionary trades by the reporting person, and will be sold, or were sold, as applicable, for the limited purpose of satisfying tax withholding obligations.
Date of Notice	05/01/2023
Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1	02/24/2023
ATTENTION:	

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature /s/ Richard Pulik

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)